BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on noninvasive gene expression tests to monitor immune-mediated conditions, today announced that clinical investigators have presented results demonstrating the potential for extended utility of AlloMap®, the company’s non-invasive genomic-based test to rule-out acute cellular rejection in heart transplant patients. These studies derive from planned secondary analyses of the IMAGE study, a clinical trial that demonstrated the comparative effectiveness of AlloMap to the standard endomyocardial biopsy (published in April 2010 in the New England Journal of Medicine). These additional new analyses were presented at the 31st Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT) this week in San Diego, Calif.
